Transplant center directory

Myeloablative/non-myeloablative transplant approaches for patients with acute/chronic leukemia, Myelodysplastic Syndrome, lymphoma, Multiple Myeloma, marrow failure and other Myeloproliferative disorders. Interests include Non Hodgkins Lymphoma, reduced-intensity regimen for older patients, and novel therapies to prevent and treat graft-versus-host disease (GVHD). A new program of haplo identical transplantation for adult patients without related or unrelated donors; Pediatric BMT includes transplant for malignant diseases such as: Leukemia, lymphoma and Neuroblastoma; and non-malignant diseases such as: Sickle Cell Anemia; Thalassemia; SCIDS and other hematologic and genetic disorders; Cell types used for pediatric transplant include: bone marrow, peripheral blood stem cells and cord blood. CAR-T and other immune effector cell therapies are available.

This center has been performing allogeneic transplants since 1987 and has been an NMDP/Be The Match transplant center since November 1999.

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 210 patients.

The actual 1-year survival of these patients is 73.9%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 69.5% and 80.8%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.